Type A monoamine oxidase is associated with induction of neuroprotective Bcl-2 by rasagiline, an inhibitor of type B monoamine oxidase

Monoamine Oxidase Inhibitors as Neuroprotective Agents in Age-Dependent Neurodegenerative Disorders

(2012) Makoto Naoi et al.   CURRENT PHARMACEUTICAL DESIGN

Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson’s disease

(2009) Makoto Naoi et al.   Expert Review of Neurotherapeutics

Mitochondrial kinases in Parkinson’s disease: Converging insights from neurotoxin and genetic models

(2009) Ruben K. Dagda et al.   MITOCHONDRION

Comparative Neuroprotective Effects of Rasagiline and Aminoindan with Selegiline on Dexamethasone-Induced Brain Cell Apoptosis

(2009) Shawna Tazik et al.   NEUROTOXICITY RESEARCH

A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease

(2009) C. Warren Olanow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comparison of neuroprotective and neurorestorative capabilities of rasagiline and selegiline against lactacystin-induced nigrostriatal dopaminergic degeneration

(2008) Wen Zhu et al.   JOURNAL OF NEUROCHEMISTRY